Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis?
Top Cited Papers
- 1 August 2017
- journal article
- review article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 77 (2), 175-187
- https://doi.org/10.1136/annrheumdis-2017-211555
Abstract
The past three decades have witnessed remarkable advances in our ability to target specific elements of the immune and inflammatory response, fuelled by advances in both biotechnology and disease knowledge. As well as providing superior treatments for immune-mediated inflammatory diseases (IMIDs), such therapies also offer unrivalled opportunities to study the underlying immunopathological basis of these conditions. In this review, we explore recent approaches to the treatment of IMIDs and the insights to pathobiology that they provide. We review novel biologic agents targeting the T-helper 17 axis, including therapies directed towards interleukin (IL)-17 (secukinumab, ixekizumab, bimekizumab), IL-17R (brodalumab), IL-12/23p40 (ustekinumab, briakinumab) and IL-23p19 (guselkumab, tildrakizumab, brazikumab, risankizumab, mirikizumab). We also present an overview of biologics active against type I and II interferons, including sifalumumab, rontalizumab, anifrolumab and fontolizumab. Emerging strategies to interfere with cellular adhesion processes involved in lymphocyte recruitment are discussed, including both integrin blockade (natalizumab, vedolizumab, etrolizumab) and sphingosine-1-phosphate receptor inhibition (fingolimod, ozanimod). We summarise the development and recent application of Janus kinase (JAK) inhibitors in the treatment of IMIDs, including first-generation pan-JAK inhibitors (tofacitinib, baricitinib, ruxolitinib, peficitinib) and second-generation selective JAK inhibitors (decernotinib, filgotinib, upadacitinib). New biologics targeting B-cells (including ocrelizumab, veltuzumab, tabalumab and atacicept) and the development of novel strategies for regulatory T-cell modulation (including low-dose IL-2 therapy and Tregitopes) are also discussed. Finally, we explore recent biotechnological advances such as the development of bispecific antibodies (ABT-122, COVA322), and their application to the treatment of IMIDs.Funding Information
- National Institute for Health Research
- Wellcome Trust
This publication has 114 references indexed in Scilit:
- Tregitope Peptides: The Active Pharmaceutical Ingredient of IVIG?Journal of Immunology Research, 2013
- The Role of p38 MAPK in the Aetiopathogenesis of Psoriasis and Psoriatic ArthritisJournal of Immunology Research, 2013
- Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled studyAnnals Of The Rheumatic Diseases, 2012
- Phase I Clinical Trial of Smad7 Knockdown Using Antisense Oligonucleotide in Patients With Active Crohn's DiseaseMolecular Therapy, 2012
- Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T‐cellsBritish Journal of Pharmacology, 2010
- Cutting Edge: Novel Function of B Cell-Activating Factor in the Induction of IL-10–Producing Regulatory B CellsThe Journal of Immunology, 2010
- A protective function for interleukin 17A in T cell–mediated intestinal inflammationNature Immunology, 2009
- Activation of natural regulatory T cells by IgG Fc–derived peptide “Tregitopes”Blood, 2008
- IL-25 regulates Th17 function in autoimmune inflammationThe Journal of Experimental Medicine, 2007
- Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trialAnnals Of The Rheumatic Diseases, 2006